7 completed, 1 active not recruiting, 1 terminated. 4 Phase 1, 4 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 3, Terminated 1 |
| Phase 2 | 4 | Completed 3, Active not recruiting 1 |
| Phase 3 | 1 | Completed 1 |
Follow Adult Acute Megakaryoblastic Leukemia: new trials by email Literature Review of Adult Acute Megakaryoblastic Leukemia trials Research Report on Adult Acute Megakaryoblastic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia Cytarabine, CHK1 Inhibitor SCH 900776, Laboratory Biomarker Analysis - Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia | Phase 2 | Completed | National Cancer Institute (NCI) | 32 | 2013-05-01 | 2016-09-01 |
| Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia Tipifarnib, Laboratory Biomarker Analysis - Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia | Phase 2 | Completed | National Cancer Institute (NCI) | 21 | 2011-05-01 | 2015-04-08 |
| Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia Azacitidine, Etoposide, Laboratory Biomarker Analysis - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Basophilic Leukemia | Phase 1 | Terminated | National Cancer Institute (NCI) | 13 | 2010-12-01 | 2015-08-20 |
| Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin, Azacitidine - Acute Myeloid Leukemia, Adult Acute Megakaryoblastic Leukemia | Phase 2 | Completed | National Cancer Institute (NCI) | 68 | 2010-07-15 | 2022-08-04 |
| Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Azacitidine, Gemtuzumab Ozogamicin - Acute Myeloid Leukemia, Adult Acute Megakaryoblastic Leukemia | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 133 | 2008-12-01 | 2026-07-01 |
| Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders Carboplatin, Laboratory Biomarker Analysis, Topotecan Hydrochloride - Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia | Phase 1 | Completed | National Cancer Institute (NCI) | 12 | 2008-02-04 | 2025-04-02 |
| Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase Bortezomib, Laboratory Biomarker Analysis, Tipifarnib - Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia | Phase 1 | Completed | National Cancer Institute (NCI) | 35 | 2006-08-01 | 2015-04-15 |
| Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia Sorafenib Tosylate - Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia | Phase 1 | Completed | National Cancer Institute (NCI) | 36 | 2005-10-01 | 2015-04-28 |
| Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission Clinical Observation, Tipifarnib - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia | Phase 3 | Completed | National Cancer Institute (NCI) | 144 | 2004-08-18 | 2026-07-14 |
Leukemia, Erythroblastic, Acute (9) · Leukemia, Megakaryoblastic, Acute (9) · Leukemia, Monocytic, Acute (9) · Leukemia, Myeloid, Acute (9) · Leukemia, Myelomonocytic, Acute (9) · Leukemia, Basophilic, Acute (3) · Leukemia, Eosinophilic, Acute (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Anemia, Refractory, with Excess of Blasts (2) · Blast Crisis (2) · Myelodysplastic Syndromes (2) · Hematologic Neoplasms (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myelomonocytic, Chronic (1) · Leukemia, Promyelocytic, Acute (1)
Bone Marrow Diseases (9) · Hematologic Diseases (9) · Hemic and Lymphatic Diseases (9) · Leukemia (9) · Leukemia, Myeloid (9) · Myeloproliferative Disorders (9) · Neoplasms (9) · Neoplasms by Histologic Type (9) · Chronic Disease (3) · Disease Attributes (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Leukemia, Lymphoid (3) · Lymphatic Diseases (3) · Lymphoproliferative Disorders (3)
Azacitidine (3) · tipifarnib (3) · Antilymphocyte Serum (1) · Bortezomib (1) · Busulfan (1) · Carboplatin (1) · Cytarabine (1) · Etoposide (1) · Gemtuzumab (1) · MK-8776 (1) · Methotrexate (1) · Mitoxantrone (1) · Observation (1) · Sorafenib (1) · Stem Cell Transplantation (1)
National Cancer Institute (NCI) (9)
United States (8) · Canada (1) · Israel (1) · Peru (1)
Jeffrey Lancet (2) · B. Smith (1) · Jorge Cortes (1) · Joseph Brandwein (1) · Keith W Pratz (1) · Ravi Vij (1) · Selina Luger (1) · Sucha Nand (1)
PMID 20952518, PMID 24092933, PMID 31212080
U01CA070095 (3), P30CA006973 (2), P30CA076292 (2), N01CM00032 (1), N01CM00071 (1), N01CM00100 (1), N01CM62203 (1), N01CM62208 (1), P30CA016672 (1), U01CA062461 (1), U01CA062491 (1), U01CA069912 (1), U10CA021115 (1), U10CA031946 (1), U10CA032102 (1)